New Molecular Glue Degrader Activated by Glutathionylation

Researchers have developed M12, a novel molecular glue degrader that is activated by glutathionylation to recruit diverse proteins for ubiquitin-mediated degradation through DCAF11. This discovery, published online in Nature on August 5, 2026, reveals a glutathione-dependent mechanism that significantly broadens the scope of targeted protein degradation across multiple substrates. Molecular glues are a class of small molecules that can induce proximity between proteins that do not normally interact, thereby hijacking cellular machinery to target specific proteins for degradation. This approach has emerged as a powerful therapeutic strategy, particularly in oncology, for tackling previously undruggable targets.

The newly identified molecular glue, M12, functions by binding to DCAF11, a substrate recognition component of the CUL4-DDB1-ROC1 E3 ubiquitin ligase complex. Upon activation by glutathionylation, M12 facilitates the formation of a ternary complex involving DCAF11, the target protein, and the E3 ligase. This complex then facilitates the ubiquitination of the target protein, marking it for degradation by the proteasome. Glutathionylation is a post-translational modification where glutathione, a tripeptide antioxidant, is covalently attached to a protein, typically on cysteine residues. This modification can alter protein function, localization, or stability, and in the case of M12, it acts as a crucial trigger for its degradation activity.

This glutathione-dependent activation mechanism is particularly significant because it offers a new layer of control and specificity for molecular glue degraders. Glutathione levels are tightly regulated within cells and can fluctuate in response to cellular stress or metabolic state. By linking the activity of M12 to glutathionylation, the researchers have engineered a degrader whose efficacy might be modulated by the cellular redox environment. This could potentially lead to more precise therapeutic interventions, targeting specific cellular conditions or disease states where glutathionylation is altered.

The ability of M12 to recruit diverse proteins to DCAF11 for degradation underscores its broad applicability. Unlike some molecular glues that are specific for a single target or a narrow range of targets, M12's mechanism suggests it can be adapted to target a wider array of proteins. This versatility is a key advantage for developing new therapeutics, as it opens up possibilities for addressing complex diseases with multiple contributing protein factors. The research published in Nature, with the DOI 10.1038/s41586-026-10873-1, provides a detailed molecular understanding of this novel degradation pathway, paving the way for further development and application of glutathionylation-activated molecular glues.